| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA808: Fenfluramine for treating seizures associated with Dravet syndrome |
|
Medicine details |
|
| Medicine name | fenfluramine (Fintepla®) |
| Formulation | 2.2 mg/ml oral solution |
| Reference number | 2513 |
| Indication | Treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older |
| Company | Zogenix International, Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/12/2020 |
| NICE guidance | TA808: Fenfluramine for treating seizures associated with Dravet syndrome |